Home / Intelligence / Scientific Publications / U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims
Prader-Willi syndrome (PWS) is a complex developmental genetic disorder associated with hypotonia, poor feeding in neonates, onset of hyperphagia in early childhood, and shorter overall life expectancy. Prior epidemiology studies of PWS have examined smaller populations, with limited research in a US population. The aim of this study was to provide a contemporary estimate of PWS prevalence and annual all-cause mortality in the US using a large administrative medical claims dataset.
Authors
Shawn McCandless, Marissa Suh, David Yin, Michael Yeh, Shawn Czado, Sina Aghsaei, Justin Li, Kevin Francis, Nandini Hadker, Diane Stafford
Journal
Journal of the Endocrine Society; Volume 4; Issue Supplement_1; April-May 2020
Related Intelligence
Blog
Operationalizing Generative AI in Life Sciences—Trinity Life Sciences Included in Everest Group Report
The transformative potential of generative AI (GenAI) within the life sciences industry is highlighted in Everest Group’s report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.” Fifteen companies were selected for inclusion across three categories: To be included in the report, providers had to have been profiled in past Everest Group PEAK Matrix® […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
May 21, 2025 | 1:00 – 1:45 PM ET
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Sign Up Now